ABSTRACT
The last two decades have witnessed dramatic fluctuations in the fortunes of hormone replacement therapy (HRT). Not only have overall prescriptions oscillated in a spectacular fashion, but constituent drugs and preferred modes of administration, and the underlying rationale and emphasis of appropriate indications for use, have changed. These changes have occurred partly in response to the expanding epidemiological evidence on aspects of the purported benefits and risks of the therapy, particularly in relation to longer term use.
